Auranofin synergizes with the PARP inhibitor olaparib to induce ROS-mediated cell death in mutant p53 cancers
Source
Antioxidants - ISSN 2076-3921-12:3 (2023) p. 1-24
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer
Source
Oncoimmunology - ISSN 2162-402X-12:1 (2023) p. 1-11
Optimization of the solvent and in vivo administration route of auranofin in a syngeneic non-small cell lung cancer and glioblastoma mouse model
Source
Pharmaceutics - ISSN 1999-4923-14:12 (2022) p. 1-18
The prognostic impact of the immune signature in head and neck squamous cell carcinoma
Source
Frontiers in immunology - ISSN 1664-3224-13 (2022) p. 1-18
Expression of SARS-CoV-2-related surface proteins in non-small-cell lung cancer patients and the influence of standard of care therapy
Source
Cancers - ISSN 2072-6694-14:17 (2022) p. 1-15